Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Oramed Pharmaceuticals logo
$2.09 -0.07 (-3.24%)
As of 07/8/2025 04:00 PM Eastern

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Key Stats

Today's Range
$2.09
$2.17
50-Day Range
$2.09
$2.38
52-Week Range
$1.82
$3.09
Volume
104,189 shs
Average Volume
141,854 shs
Market Capitalization
$85.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Oramed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

ORMP MarketRank™: 

Oramed Pharmaceuticals scored higher than 5% of companies evaluated by MarketBeat, and ranked 910th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.03) to ($0.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oramed Pharmaceuticals is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oramed Pharmaceuticals is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oramed Pharmaceuticals has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Oramed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.35% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 2.88%, indicating that investor sentiment is improving.
  • Dividend Yield

    Oramed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oramed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.35% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 2.88%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

  • Read more about Oramed Pharmaceuticals' insider trading history.
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Oramed Pharm Extends Stock Buyback Program
See More Headlines

ORMP Stock Analysis - Frequently Asked Questions

Oramed Pharmaceuticals' stock was trading at $2.42 at the beginning of the year. Since then, ORMP stock has decreased by 13.6% and is now trading at $2.09.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its earnings results on Thursday, May, 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.16. The biotechnology company had revenue of $2 million for the quarter.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
5/15/2025
Today
7/08/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORMP
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.06 million
Pretax Margin
-1,225.60%

Debt

Sales & Book Value

Annual Sales
$1.34 million
Price / Cash Flow
N/A
Book Value
$3.61 per share
Price / Book
0.59

Miscellaneous

Free Float
35,254,000
Market Cap
$86.60 million
Optionable
Optionable
Beta
1.59

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ORMP) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners